Recent News
Our Product
Our first approved product is indicated for the acute treatment of migraine with or without aura in adults.
Our Focus
SMART Platform
Satsuma’s SMART (Simple MucoAdhesive Release Technology) Platform is a transformative solution designed to overcome the inherent efficacy and administration limitations of current treatment formulations.
Publications
Our Research
Scientific publications from Satsuma regarding the use of DHE in the acute treatment of migraine.
Press Releases
Apr 30, 2024
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Nov 26, 2024